RMTG Regenerative Medical Technology Group Inc.
Retail-Retail Stores, NEC · OTC · SEC CIK 1760026 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY94.3%
TTM net income YoY-155.5%
TTM EPS YoY-55.6%
Revenue 3-yr CAGR66.0%
Net income 3-yr CAGR—
Margins
Gross margin59.8%
Operating margin0.5%
Net margin-101.2%
FCF margin-6.2%
EBITDA margin4.3%
Returns
ROE—
ROA-184.4%
ROIC (approx.)—
Asset turnover1.82x
Leverage & solvency
Liabilities / assets771.0%
Debt / equity—
Current ratio0.05x
Interest coverage0.00x
Cash quality & payout
Operating cash flow / net income-0.03x
Accruals ratio-189.6%
Payout ratio—
Capex / revenue9.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.02M | $2.64M | $1.57M | $1.18M | $983,318 | $1.36M | $1.51M | $986,308 |
| Cost of revenue | $1.44M | $872,862 | $792,427 | $678,977 | $397,686 | $420,447 | $530,640 | $239,247 |
| Gross profit | $2.58M | $1.77M | $779,495 | $501,557 | $585,632 | $943,894 | $980,183 | $747,061 |
| SG&A expense | $619,164 | $475,812 | $389,318 | $277,696 | $207,449 | $245,566 | $113,111 | $264,078 |
| Operating income | $565,977 | $229,783 | -$306,274 | -$445,761 | -$250,087 | $134,960 | $380,618 | $19,648 |
| Interest expense | $2.23M | $2.19M | $2.01M | $3.49M | $1.06M | $895,850 | $1.02M | $905,572 |
| Net income | -$2.91M | -$876,274 | -$1.39M | -$4.35M | -$1.44M | -$760,039 | -$638,186 | -$887,146 |
| EBITDA | $656,787 | $327,477 | -$207,931 | -$369,683 | -$195,255 | $186,774 | $352,806 | $108,476 |
| EPS (basic) | -0.22 | -0.07 | — | -0.35 | -0.12 | -0.06 | — | -0.07 |
| EPS (diluted) | -0.22 | -0.07 | — | -0.35 | -0.12 | -0.06 | — | -0.07 |
| Weighted avg. shares (diluted) | 13.22M | 13.14M | — | 12.54M | 12.54M | 12.54M | — | 12.54M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.32M | $1.06M | $956,718 | $1.19M | $1.61M | $1.22M | $1.17M | $836,427 |
| Receivables | $110,244 | $34,821 | $43,815 | $114,006 | $36,676 | $16,306 | $22,605 | — |
| Inventory | $481,168 | $298,201 | $159,277 | $155,886 | $105,688 | $22,829 | $10,115 | — |
| Current assets | $2.28M | $1.57M | $1.22M | $1.51M | $1.91M | $1.45M | $1.25M | — |
| PP&E, net | $1.09M | $1.11M | $870,759 | $677,544 | $504,409 | $424,274 | $451,703 | — |
| Goodwill | $1.68M | $1.68M | $1.68M | $1.68M | $1.68M | $1.68M | $1.68M | — |
| Intangibles | $12,694 | $37,079 | $61,464 | $85,849 | $110,234 | $134,619 | $159,004 | — |
| Total assets | $5.85M | $5.01M | $4.49M | $4.52M | $4.49M | $3.98M | $3.82M | — |
| Current liabilities | $42.61M | $38.20M | $38.13M | $17.27M | $30.54M | $29.88M | $28.97M | — |
| Total liabilities | $45.11M | $40.63M | $40.54M | $34.57M | $33.51M | $32.10M | $31.18M | — |
| Shareholders' equity | -$39.26M | -$36.36M | -$36.05M | -$30.05M | -$29.02M | -$28.12M | -$27.36M | -$26.72M |
| Shares outstanding | 13.74M | 13.14M | 13.14M | 12.54M | 12.54M | 12.54M | 12.54M | — |
| Cash flow statement | ||||||||
| Operating cash flow | $331,974 | $102,124 | $38,196 | -$203,731 | -$598,093 | $57,109 | $379,393 | $272,942 |
| Capital expenditure | $43,499 | $315,394 | $267,172 | $224,829 | — | — | $50,000 | $53,608 |
| Free cash flow | $288,475 | -$213,270 | -$228,976 | -$428,560 | — | — | $329,393 | $219,334 |
| Investing cash flow | -$43,499 | -$315,394 | -$267,172 | -$224,829 | — | — | -$50,000 | -$53,608 |
| Financing cash flow | -$26,619 | $318,000 | $0 | $0 | — | — | — | — |
| Depreciation & amortization | $90,810 | $97,694 | $98,343 | $76,078 | $54,832 | $51,814 | -$27,812 | $88,828 |
Free plan shows the latest 8 periods; Pro shows all 34 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.